Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 (Cadonilimab) in recurrent or metastatic cervical cancer
NCT04380805Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Jul 2020
- Primary completion
- Dec 2022
- Modality
- Bispecific Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Cervical Cancer (CC), sponsored by Akeso, Inc. Primary endpoint: Objective Response Rate assessed by IRRC up to 2 years. Started Jul 2020; status: completed.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04380805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380805.